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Kerstin Ahrens1, Nina Graumann1, Hansjo¨rg Baurecht1, Karina Reiss1, Jens-Michael Schro¨der1,
Ehrhardt Proksch1 and Ulf Meyer-Hoffert1
The proteolytic regulation of the desquamation process by kallikrein-related peptidases (KLKs) is crucial for
epidermal barrier function, and elevated KLK levels have been reported in atopic dermatitis. KLKs are controlled
by specific inhibitors of the serine protease inhibitor of Kazal-type (Spink) family. Recently, SPINK6 was shown to
be present in human stratum corneum. In order to investigate its role in epidermal barrier function, we studied
mouse Spink6. Sequence alignment revealed that the Kazal domain of Spink6 is highly conserved in animals.
Recombinant Spink6 efficiently inhibited mouse Klk5 and human KLK2, KLK4, KLK5, KLK6, KLK7, KLK12, KLK13, and
KLK14, whereas human KLK1 and KLK8 were not inhibited. Spink6 was expressed in mouse epidermis mainly in
the stratum granulosum, and the inner root sheath of hair follicles. Stimulation with flagellin, EGF, and IL-1b did
not alter Spink6 expression, whereas stimulation with tumor necrosis factor-a (TNFa)/IFNg and all-trans retinoic
acid resulted in a significant downregulation of Spink6 expression in cultured primary mouse keratinocytes.
Mechanically and metabolically induced skin barrier dysfunction resulted both in a downregulation of Spink6
expression. Our study indicates that Spink6 is a potent inhibitor of KLKs and involved in skin barrier function.
Journal of Investigative Dermatology (2014) 134, 1305–1312; doi:10.1038/jid.2013.502; published online 19 December 2013
INTRODUCTION
Epidermal proteases are involved in many processes of the
epidermal barrier including processing of structural proteins
like filaggrin and cleavage of desmosomal proteins. Members
of the kallikrein family turned out to be involved in many of
these proteolytic processes and their insufficient regulation
can lead to severe diseases (Meyer-Hoffert, 2009).
Kallikrein-related proteases (KLKs) are the largest group of
tryptic and chymotryptic serine proteases. A series of duplica-
tion and mutation events gave rise to the KLK gene family with
interspecies differences in number and function (Pavlopoulou
et al., 2010). In humans, they are encoded by 15 genes on
chromosome 19q13.4, whereas they comprise 24 genes in
mouse (Olsson and Lundwall, 2002) and 20 genes in rat
(Wines et al., 1989). At least eight KLKs are expressed in
human skin, among which KLK5, KLK7, KLK8, and KLK14
have been reported to be most important (Hansson et al.,
2002; Komatsu et al., 2003, 2005; Eissa et al., 2011). KLKs are
capable of cleaving corneodesmosomes and are thought to be
key regulators of the desquamation process (Simon et al.,
2001; Caubet et al., 2004; Borgono et al., 2007). More
recently, they have been described to be involved in
initiating inflammatory processes by activation of proteinase-
activated receptors and processing of proinflammatory
cathelicidin. These events have an important role in the
pathophysiology of eczema (Briot et al., 2009) and rosacea
(Meyer-Hoffert and Schroder, 2011). The activity of the KLKs is
regulated by the pH and specific protease inhibitors (Fischer
and Meyer-Hoffert, 2013). The importance of KLK regulation
by protease inhibitors has been revealed impressively in
Netherton Syndrome (NS; OMIM (Online Mendelian Inheri-
tance in Man) 256500), an autosomal recessive disorder
caused by mutations in the gene serine protease inhibitor
Kazal-type 5 (spink5) (Chavanas et al., 2000). NS presents as
an ichthyosiform dermatosis with variable erythroderma, hair-
shaft defects (bamboo hair), atopic features, and growth
retardation (Griffiths et al., 1998). Lymphoepithelial Kazal-
type-related inhibitor (LEKTI), encoded by spink5, includes in
its primary structure 15 different serine protease inhibitory
domains (Magert et al., 1999), and many of them have been
shown to be potent inhibitors of KLKs (Furio and Hovnanian,
2011). Spink5-deficient mice mimic NS through degradation
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of desmoglein 1 by epidermal protease hyperactivity
(Descargues et al., 2005).
In addition to LEKTI, SPINK6 and SPINK9 have been
identified to be expressed in human skin (Brattsand et al.,
2009; Meyer-Hoffert et al., 2009, 2010). Unlike spink5,
spink6 and spink9 encode a single-domain Kazal-type
inhibitor. Whereas SPINK9 exhibited only inhibition against
KLK5, SPINK6 inhibited various KLKs very efficiently (Kantyka
et al., 2011). Although SPINK9 expression is limited to
palmoplantar sites, SPINK6 expression was identified to be
expressed in the stratum granulosum at all body sites investi-
gated similar to LEKTI. These findings and the fact that SPINK6
inhibits desquamation in an ex vivo model suggested that
SPINK6 might have an important role in skin barrier
homeostasis. To further elucidate its role, we characterized
the mouse homolog and investigated its expression and
regulation in epidermal barrier dysfunction.
RESULTS
The Kazal-type domain of Spink6 is highly conserved
As there are interspecies differences among the number and
sequences of spink genes, we first analyzed the conser-
vation of the Spink6 in silico. Spink6 is highly conserved
among various species, from frogs to humans (Figure 1),
suggesting an essential role in cellular function. Human and
mouse Spink6 show 92% of homology. The highest conserva-
tion among these species is shown in the protease binding
loop region.
Spink6 is expressed in the upper epidermis and in skin
appendages
Immunohistochemical staining revealed expression of Spink6
in the epidermis and skin appendages (Figure 2). Highest
expression was observed in the stratum granulosum of the
skin. Staining was prominent in the regions of paws and foot
pads and in the nail bed epidermis. Moreover, the inner root
sheath of hair follicles and the tongue showed positive Spink6
immunoreactivity. In the hair follicle, the expression of Spink6
was limited to the lower third of the follicle. Western blot
analysis of a tongue extract revealed immunoreactive bands at
the height of recombinant Spink6.
Spink6 is a potent inhibitor of kallikrein-related peptidases
As mouse Spink6 exhibited high homology to human SPINK6,
we speculated that their inhibition profiles would be rather
similar. Recombinant KLKs were first characterized by their
ability to hydrolyze fluorogenic substrates and kinetic para-
meters toward their inhibition by recombinant mouse Spink6
were determined (Table 1). Recombinant Spink6 inhibited
various KLKs very efficiently with inhibition of human KLK5
and KL14 in the pM range. The tryptic mouse KLK5 and the
human KLK2, KLK4, KLK6, KLK12, and KLK13 as well as the
chymotryptic human KLK7 were inhibited in the nM range. All
inhibitions fulfilled the criteria of so-called tight-binding
inhibition. Human KLK1 and KLK8 were not inhibited by
Spink6. The addition of recombinant Spink6 to natural
mouse epidermal keratinocytes significantly reduced the
hydrolysis activity of the trypsin-like substrate GPR-AMC to
comparable levels as inhibition by 1 mM a1-antitrypsin
(Figure 3). The following enzymes were not inhibited by a
1,000-fold molar excess of Spink6: cathepsin G, chymotryp-
sin, mast cell chymase, matriptase, plasmin, trypsin, prostasin,
and thrombin.
Release of soluble Spink6 is downregulated by TNFa/IFNc and
retinoic acid
In order to study the regulation of spink6 mRNA and protein
release, normal mouse epidermal keratinocytes were cultured
from newborn mice and differentiated for 7 days by calcium
treatment. Differentiation was confirmed by real-time PCR that
showed significant increase in keratin-10 expression (data not
shown). Stimulation for 24 hours with all-trans retinoic acid,
tumor necrosis factor-a (TNFa) in combination with IFNg,
Pseudomonas aeruginosa–derived flagellin (Meyer-Hoffert
et al., 2011), EGF, and IL-1b did not lead to significant
changes in spink6 mRNA expression level. However, release
of soluble Spink6 protein was significantly reduced by retinoic
acid and TNFa/IFNg treatment (Figure 4).
Mechanical and metabolic injury to the skin barrier leads to
decreased expression of Spink6
Acute barrier disruption, induced by tape stripping and
acetone treatment, resulted in a decreased expression of
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Figure 1. Serine protease inhibitor Kazal-type 6 (Spink6) is highly conserved among different animals. Multiple sequence alignment of Spink6 is shown. The
alignment was generated by using M-COFFEE and displayed by using GeneDoc. Identical residues are boxed in black, and gray boxes mark partially conserved
residues. The darker the shading, the more the amino acids are conserved among repeat domains. The arrow indicates the P1 position of the inhibitor domain.
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Spink6 immunoexpression and a significant downregulation of
Spink6 mRNA expression after tape stripping (Figure 5),
whereas acetone treatment showed only a tendency of down-
regulation (P¼ 0.0519). In order to study Spink6 changes
during chronic barrier injury, an established metabolic injury
model was used. Mice fed with an essential fatty acid–
deficient diet develop a red and scaly skin, impaired epider-
mal differentiation, and a disturbed skin barrier function (Bibel
et al., 1989; Proksch et al., 1992). An essential fatty acid–
deficient diet resulted in a significantly decreased mRNA
expression of Spink6 (Figure 5).
DISCUSSION
Herein, we describe mouse Spink6 as a potent inhibitor of
KLKs and its expression and regulation in mouse skin. On the
first view, mouse Spink6 turned out to be similar to human
SPINK6. Mouse Spink6 efficiently inhibited distinct KLKs.
Especially, the inhibitions of KLK5 and KLK14 in the pM range
are the lowest ones reported so far for KLK inhibition. In
comparing mouse Spink6 with the recently described mouse
Spink12, it is interesting that Spink12 did not inhibit any of the
KLKs tested (Reiss et al., 2011). However, Spink12 was able to
inhibit the tryptic-like activity in cultured mouse keratinocytes,
which led us to speculate that mouse KLKs might be different
from human ones. Therefore, mouse Klk5 was included in this
study. Indeed, the inhibition constants of mouse Klk5 was
different from human KLK5 for mouse Spink6 and human
SPINK6 but they were in the same order of magnitude. Mouse
Klk5 was not inhibited by mouse Spink12 in our hands (data
not shown). Thus, a detailed analysis of mouse Klks is needed
before interpretation of interspecies results when it comes to
Klk inhibition.
In comparing the inhibition of human KLKs by mouse
Spink6 and human SPINK6, some dramatic differences
became evident. Mouse Spink6 inhibited human KLK2 in
the nM range, whereas human SPINK6 did not inhibit KLK2
(Kantyka et al., 2011). Moreover, human KLK7 was inhibited
by mouse Spink6 in the nM range, whereas human SPINK6
was B1,000-fold less potent. Interestingly, human KLK5 was
better inhibited by mouse Spink6, whereas inhibition of
mouse KLK5 by human SPINK6 was superior. This might be
caused by the P4 and P3’ positions of the deduced binding site
of Spink6 (Phe and Asp, respectively) that differ from that of
SPINK6 (Tyr, and Asn, respectively). Both positions belong to
the 12 specific amino acids of Kazal-type inhibitors that in
general build the contact points to the proteinase (Laskowski
et al., 2003). Another possibility is that other regions of the
Spink molecule are involved in the inhibition, thus revealing a
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Figure 2. Serine protease inhibitor Kazal-type 6 (Spink6) is expressed at the upper epidermis and in skin appendages. Immunohistochemical analyses of
Spink6 expression in paraffin-embedded tissue sections. (a) Skin from the back region, (b) control with incubation of the preimmune Ig instead of the anti-Spink6
antibody, (c) plantar skin of the foot pad, (d, e, f) hair follicle, (g) claw region, and (h) tongue. Bars¼ 100mm. (i) Western blot analyses using affinity-purified
polyclonal Spink6 antibody of a tongue extract in comparison with recombinant mouse Spink6.
J Fischer et al.
Spink6 in Epidermal Barrier Injury
www.jidonline.org 1307
second unknown binding site of inhibitor and protease.
Structural investigations are necessary to solve this question.
Taken the similarity of KLK activities, our results point to
promising approaches to design specific inhibitors and
substrates for these proteases that might be useful for further
diagnostic and therapeutic usage.
The expression of Spink6 in the stratum granulosum is
similar to the expression of SPINK6 and SPINK5/LEKTI and
suggests that it functions in the epidermal barrier complex.
Spink6 expression was prominent at plantar sites as it was also
observed for mouse Spink12, the ortholog to human SPINK9
(Reiss et al., 2011), human SPINK6, and SPINK9 (Meyer-
Hoffert et al., 2009). These observations point to a crucial role
of Spinks in the formation of palmoplantar skin with its
specific need to resist mechanical stress. It will be interesting
to study the role of KLKs and its protease inhibitors at this
particular localization in diseases such as hand eczema and
palmoplantar psoriasis. Comparable to SPINK5/LEKTI, Spink6
is present in the inner root sheath of the hair follicle. We also
detected mouse Spink12, the mouse ortholog to human
SPINK9, in this localization (Supplementary Figure S1e, f
online). On the other hand, human SPINK6 was not detected
in this localization (Meyer-Hoffert et al., 2010). The intensive
expression of Spink6 in the nail bed region is remarkable. In
the human nail bed, SPINK6 and SPINK9 expression was also
detected (Supplementary Figure S1a-d online). The fact that
patients with NS do not show nail abnormalities points to a
minor role of LEKTI/SPINK5 in nail formation. We speculate
that Spink6 might be involved in correct nail growth and
formation.
Interestingly, the expression of Spink6 was reduced by
barrier injury. Acute barrier disruption by tape stripping,
acetone treatment, as well as chronic metabolic damage
resulted in downregulation of Spink6 expression. In similar
experiments, we previously observed upregulation of antimi-
crobial peptides (Ahrens et al., 2011). Downregulation of
SPINK6 was seen in skin diseases such as atopic dermatitis
and psoriasis (Meyer-Hoffert et al., 2010). The decreased
expression of Spink6 after barrier injury can be partially
explained by our in vitro investigations of Spink6 regulation
in cultured mouse keratinocytes. Stimulation with TNFa
together with IFNg resulted in a decrease of released Spink6
protein from cultured keratinocytes. However, further studies
are needed to decipher the molecular mechanism, and how
Spink6 mRNA expression is reduced during epidermal barrier
disruption.
Table 1. Kinetic parameters of KLKs used in this study and inhibition of KLKs by recombinant mouse Spink6
Mouse Spink6
Enzyme Substrate KM (lM) Kcat (1 s
 1) Kcat/KM Ki (nM) Human SPINK6 Ki (nM)
hKLK1 GPR-AMC 67 0.39 5.87 103 NI NI
hKLK2 PFR-AMC 74 0.68 9.20 103 7.1 NI
hKLK4 VPR-AMC 73 1.55 21.2 103 61 27.3
hKLK5 VPR-AMC 774 0.34 0.44 103 0.013 1.33
mKlk5 PFR-AMC 276 0.34 1.22 103 0.31 0.010
hKLK6 VPR-AMC B85,000 ND ND 32 140
hKLK7 RPT-AMC 342 0.11 0.33 103 4.6 1,070
hKLK8 VPR-AMC 365 1.13 3.1 103 NI NI
hKLK12 VPR-AMC 107 0.12 1.1 103 0.47 1.1
hKLK13 GPR-AMC 671 0.31 0.50 103 6.2 0.3
hKLK14 PFR-AMC 160 1.60 10.0 103 0.043 0.47
Abbreviations: KLK, kallikrein-related peptidase; ND, not done; NI, no inhibition; Spink6, serine protease inhibitor Kazal-type 6.
Inhibition constants were compared with recently assessed inhibition constants of human SPINK6 (Kantyka et al., 2011).
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Figure 3. Inhibition of trypsin-like protease activity of normal mouse
epidermal keratinocytes by serine protease inhibitor Kazal-type 6 (Spink6).
Isolated keratinocytes were cultivated in 48-well plates until they reached 90%
confluence and differentiated for 7 days by 1.5 mM Ca2þ stimulation. After
adding 1 mM of each inhibitor and 0.05 mM GPR-AMC, reaction velocities were
monitored for 4 hours of 8 replicates. Initial velocities were plotted with their
SD. *Po0.05.
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Downregulation of KLK inhibitors like Spink6 might be
important for the pathogenesis of atopic dermatitis as it may
result in increased activities of KLK5 and KLK14. KLK5 and
KLK14, but not KLK8, have been reported to activate the
protease-activated receptor-2 (Stefansson et al., 2008), a
signaling receptor in epidermal inflammation (Steinhoff
et al., 2005) and regulator of epidermal barrier function
(Hachem et al., 2006). Recently, KLK5 was identified to
induce atopic dermatitis–like lesions through activation of
the protease-activated receptor-2 by inducing thymic stromal
lymphopoietin expression in NS patients (Briot et al., 2009).
Increased trypsin-like proteolytic activity was reported in
atopic dermatitis lesions (Voegeli et al., 2009) that could not
be explained only by differences in KLK expression (Voegeli
et al., 2011) and might, in part, be the result of decreased
Spink6 expression due to barrier injury. Inhibition of KLKs
might be a potential therapeutic strategy in patients with NS
and atopic dermatitis. Therefore, inhibitors such as the
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Figure 5. Serine protease inhibitor Kazal-type 6 (Spink6) is downregulated
upon barrier damage. Immunohistochemical staining of Spink6 in mice (a)
before and 6 hours after stratum corneum barrier injury, (b) by acetone
treatment, (d) repeated tape stripping, and (f) in metabolically barrier-disrupted
skin of mice fed an essential fatty acid–deficient (EFAD) diet. Bars¼ 100mm.
Relative mRNA expression of Spink6 to TATA-binding protein (TBP) expression
was quantified by real-time PCR after (c, n¼6 different mice) acetone
treatment, (e, n¼5) tape stripping, and (g, n¼ 6 and n¼ 14 for control) EFAD
diet. Mann–Whitney test. *Pp0.05; **Pp0.01.
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Figure 4. Release of soluble serine protease inhibitor Kazal-type 6 (Spink6) is
downregulated by tumor necrosis factor-a (TNFa)/IFNc and retinoic acid in
differentiated normal mouse epidermal. Murine primary keratinocytes were
cultivated in 12-well plates until they reached 90% confluence and
differentiated for 7 days by sorbitol (75 mM) and 1.5 mM Ca2þ stimulation.
Next, they were challenged with growth factors, microbial products, and
biological stimuli for 24 hours including 1mg ml 1 flagellin, 10 ng ml 1 TNFa
in combination with 10 ng ml 1 IFNg, 20 ng ml1 murine EGF, 10 ng ml1
IL-1b, and 100 nM all-trans retinoic acid. (a) The mRNA expression was
assessed by quantitative real-time PCR (qRT–PCR) and normalized to
glyceraldehyde 3-phosphate dehydrogenase (gapdh) mRNA. The shown data
are the fold change relative to the unstimulated control and are mean±SEM
(nX3), Mann–Whitney test *Pp0.05. (b) Spink6 protein levels were measured
in cell culture supernatants using quantitative ELISA. The shown data are the
Spink protein levels mean±SEM (nX3), Mann–Whitney test *Pp0.05.
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KLK7-inhibiting nitrogen-containing heterocyclic compounds
were designed (Sotiropoulou and Pampalakis, 2012) that
promoted the recovery of mouse skin barrier disruption
(Flohr et al., 2010). Such an inhibitor also exerted anti-
inflammatory effects in a phorbol 12-myristate-13-acetate–
induced irritant dermatitis model in mice (Flohr et al., 2010),
although KLK5-induced protease-activated receptor-2 activation
is not directly inhibited by this compound. A clinical trial is
currently under investigation to test the therapeutic potential
in atopic dermatitis and NS (www.clinicaltrials.gov identifier
NCT01428297). Maybe, KLK inhibitors including trypsin-like
KLKs such as Spink6 might have additional therapeutic
benefits.
In conclusion, we characterize the mouse Spink6 as a
potent inhibitor of distinct KLKs in mouse skin and show that
its expression is reduced after epidermal barrier injury, which
suggests that Spink6 might be involved in epidermal barrier
function.
MATERIALS AND METHODS
Bioinformatics
Homology search was performed using the tBLASTn algorithm as
provided by the Ensemble BlastView server (http://useast.ensembl.org/
index.html). The BLAST algorithm (Altschul et al., 1997) was used for
the determination of gene structure as provided by Ensemble UCSC
Genome Browser (http://genome.ucsc.edu/cgi-bin/hgBlat). Subsequent
sequence manipulations utilized the online BLAST 2 Sequences
(Tatusova and Madden, 1999). Protein domains were analyzed using
the SMART server (Schultz et al., 1998) and SignalP 3.0 (http://
www.cbs.dtu.dk/services/SignalP/), respectively. Multiple sequence
alignments were performed using the ClustalW2 program and
edited with GeneDoc (http://www.psc.edu/biomed/genedoc).
Recombinant protein production
The recombinant expression of Spink6 (residues 25 to 105) in E. coli
was performed by molecular subcloning of Spink6 complementary
DNA into the prokaryotic expression vectors pSUMO3 (LifeSensors,
Malvern, PA), as previously described (Meyer-Hoffert et al., 2010). To
subclone the Spink6 into the expression vector pSUMO3, nested PCR
was performed with TITANIUM Taq Polymerase (Clontech-Takara
Bio Europe, Saint-Germain-en-Laye, France) with the outer primers
and Pfu DNA polymerase (Promega, Mannheim, Germany) for the
PCR with the inner primers (outer primer forward 50-AGCAAAGCA
GCCTTGATCTGAGTGA-30, reverse 50-AGACCCACACGGAGAAAA
AGTTGTG-30; inner primer forward 50-AAGGTCTCAAGGTGGAGG
ACAGGACAAAAGAG-30, reverse 50-AAGGATCCTCAGCATTTCCC
ACGATGC-30). The inserts were gel purified and inserted into the
pSUMO3 vector. Positive clones were identified and verified by
sequencing. The plasmids were introduced into the E. coli host strain
BL21 (DE3) pLys (Novagen, Darmstadt, Germany). Subsequently,
these were grown at 37 1C in lysogen broth medium containing
appropriate antibiotics. Expression of the recombinant protein was
induced with 1 mM isopropyl thio-b-D-galactoside for 2.5 hours at
30 1C. Bacteria were harvested by centrifugation at 6,000 g for
5 minutes at 4 1C, lysed by sonication, and then centrifuged at
12,000 g for 30 minutes at 4 1C. Recombinant proteins were
trapped with Ni2þ prepared columns (1 ml HisTrap HP column, GE
Healthcare, Munich, Germany) and Ni2þ -affinity column-bound
proteins were subjected to preparative reversed-phase HPLC with a
column (SP250/10 Nucleosil 300-7 C8; Macherey-Nagel, Du¨ren,
Germany) that was previously equilibrated with 0.1% (v/v)
trifluoroacetic acid in HPLC-grade water containing 10% 2-
propanol. The polyhistidine-tagged fusion proteins were eluted with
a gradient of increasing concentrations of 2-propanol containing
0.1% (v/v) trifluoroacetic acid (flow rate, 3 ml min 1). Fractions
containing UV (215 nm)-absorbing material were collected, lyophi-
lized, and analyzed by ESI-qTOF mass spectrometry (Micromass,
Manchester, UK). Purified histidine-tagged pET-fusion proteins were
then digested with SUMO protease 2 (LifeSensors) according to the
manufacturer’s suggestion, but instead of phosphate-buffered saline,
20 mM phosphate buffer was used for digestion. Linearized Spink6
refolding was done by incubating 4 mM reduced glutathione and
1 mM oxidized glutathione per 0.2 mg ml 1 peptide in 20 mM
phosphate buffer (pH 7.6) for at least 14 hours at 4 1C. For
separation of proteins, a reversed-phase HPLC with a Jupiter 5mm
C4 300A column (Phenomenex, Aschaffenburg, Germany) was used.
Fractions of each peak were collected and purity of recombinant
Spink6 was determined by SDS-PAGE. Masses of fusion proteins and
recombinant Spink6 peptides were analyzed by ESI-qTOF mass
spectrometry. Concentrations of proteins present in HPLC fractions
were estimated by UV absorbance at 280 nm by using Nanodrop
(Thermo Fisher Scientific, Dreieich, Germany).
Production of antibody
Polyclonal antiserum was generated in a goat against recombinant
mouse Spink6 as described previously (Wu et al., 2009). Briefly, a
total of 1.0 mg of Spink6 was conjugated to maleimide-activated
keyhole limpet hemocyanin (1:1, w/w) and was used together with
1.0 mg unbound Spink6 as immunogens. The antibody was affinity-
purified against Spink6 that was covalently bound to the HiTrap NHS-
activated HP 1 ml column, respectively. Activity of the purified
antibodies was tested against the recombinant mouse Spink6 and
against the pSUMO3 tag protein.
Immunohistochemistry
Paraffin-embedded 5mm tissue sections were treated as described
previously (Wu et al., 2009). The sections were stained with affinity-
purified polyclonal goat Spink6-antibody (final concentration
2 ngml 1) followed by a biotinylated rabbit anti-goat IgG secondary
antibody (1:100 dilution; Dako Cytomation, Hamburg, Germany) and
subsequently incubated with Vector Universal DAB kit (Hamburg,
Germany). Counterstaining was done with hematoxylin. Negative
controls were done by incubating the slides with preimmune serum
instead of the anti-Spink6 antibody.
Western blot analysis
Isolated mouse tongue was homogenized in phosphate-buffered
saline (5ml mg 1) buffer using a SpeedMill PLUS Homogenisator
(Analytik Jena AG, Jena, Germany) four times for 30 seconds and
subsequently centrifuged at 14,000 g. The supernatant was stored
at  20 1C. For SDS-PAGE, 10ml supernatant and 100 ng recombinant
Spink6 was loaded with 3 mM dithiothreitol in the sample buffer. Anti-
Spink6 antibody (1 ngml 1) was used. The western blot was detected
using Lumi-Light (Roche Diagnostics Deutschland, Mannheim, Ger-
many). Detection time for tongue extract was set to 3 minutes instead
of 53 seconds compared with control Spink6 for better visualization.
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Determination of Michaelis constant
Recombinant human KLKs and mouse Klk5 were activated according
to the manufacturer’s protocol using lysyl endopeptidase and thermo-
lysin (R&D Systems). GPR-AMC, VPR-AMC, PFR-AMC (Bachem
Distribution Services, Weil am Rhein, Germany), and RPT-AMC
(Merck, Darmstadt, Germany) were used as fluorogenic substrates.
Thermolysin and lysyl endopeptidase did not cleave the substrates in
control experiments (data not shown). To calculate kinetic para-
meters, enzyme activities were assumed to be 100% active. Enzymes
were mixed with varying substrate concentrations. Mixtures con-
tained 0.5 nM protein concentration of each KLK and respective
substrate in the concentration range of 3 to 400mM in buffer systems
recommended by the manufacturer. All proteolytic activity assays
were performed in a Twinkle LB 970 reader (BERTHOLD TECH-
NOLOGIES, Bad Wildbad, Germany) at 355/460 nm ex/em
wavelength.
Determination of Spink6 inhibition constant Ki
All enzymes were incubated with increasing concentrations of recom-
binant mouse Spink6 for 5 minutes in buffer systems as recommended
by the manufacturer (Kantyka et al., 2011). After 5 minutes of incu-
bation, the substrate was added, resulting in final concentrations of
0.5 nM of the respective enzyme, 0.05 mM fluorogenic substrate
(Table 1), and Spink6 in increasing concentrations, in a total volume
of 200ml. The initial reaction velocities for each tested inhibitor
concentration were determined by linear regression and were sub-
sequently plotted against the inhibitor concentration. Data were
further analyzed according to the tight-binding inhibition model by
Morrison (Kantyka et al., 2011).
Real-time PCR
Total RNA for quantitative real-time PCR was isolated using PeqGold
Trifast (PEQLAB Biotechnologie, Erlangen, Germany). Complemen-
tary DNA was prepared using an oligo-d(T) primer Maxima Reverse
Transcriptase (Fermentas, Schwerte, Germany). The primer pairs used
in quantitative real-time PCR were intron spanning. To validate
quantity and quality of the template complementary DNA, control
PCR with glyceraldehyde 3-phosphate dehydrogenase (gapdh) or
TATA-binding protein (TBP) primers was performed (mSpink6 forward
50-GCAGGTGTCTTTCTGCTCCT-30, mSpink6 reverse 50-CCAGAGC
TTTTCTCCAATGC-30; mGAPDH forward 50-TGGTGAAGGTCGGTG
TGAAC-30, mGAPDH reverse 50-ATTCTCGGCCTTGACTGTGC-30;
mTBP forward 50-GTGAAGGGTACAAGGGGGTG-30, mTBP reverse
50-ACATCTCAGCAACCCACACA-30). All PCR runs were repeated at
least two times for each primer pair and at least three independent
sets of complementary DNA. The PCR reaction was performed using
SYBR Select Master Mix (Life Technologies, Darmstadt, Germany)
and StepOnePlus (Life Technologies).
Spink 6 ELISA
The 96-well plate (Maxisorb, Nunc, Copenhagen, Denmark) was
incubated with 100ml of 1mg ml 1 mSpink6 antibody overnight at
4 1C. After blocking with 1% BSA in phosphate-buffered saline/0.05%
Tween-20 followed by washing, samples and recombinant mSpink6
as standard were applied in cell culture medium for 1 hour at room
temperature. Biotinylated mSpink6 antibody (100ml of 1mg ml 1)
was applied after a second washing step. Streptavidin conjugate
(Roche, Mannheim, Germany) 1:10,000 in phosphate-buffered
saline/0.05% Tween-20 was incubated for 30 minutes at room
temperature and after a third washing step ABTS substrate (Roche)
was applied for 20–30 minutes in the dark. The measurement of the
luminescence was performed at 405/492 nm.
Mice
Hairy mice (BALB/c) were bred in the central animal facility at the
University of Kiel. Hairless SKH-1 mice (Crl:(hr/hr) BR) were supplied
by Charles River (Sulzfeld, Germany). Essential fatty acid–deficient
mice were obtained by feeding 3-week-old hairless mice
with an essential fatty acid–deficient diet for 3 to 4 weeks (Bavandi
et al., 1992), supplemented by MgSO4 7 H2O. In this study,
transepidermal water loss as a marker of skin barrier function
increased from 9.0±0.35 to 26.9±1.15 gm 2 per hour (n¼ 10,
Po0.005) (Ahrens et al., 2011). All mice were individually and
conventionally maintained in plastic cages under standardized
conditions (25 1C; relative humidity, 45–55%; circadian rhythm,
12 hours; food (standard laboratory animal chow, V1534; SSNIFF
Spezialdia¨ten, Soest, Germany); and water supplied ad libitum). The
University of Kiel Committee for Animal Care approved the study.
Culture and stimulation of normal mouse epidermal
keratinocytes
To isolate murine primary keratinocytes, the skin was detached
and incubated for 1.5 hours in 1% trypsin solution. The upper
layer was peeled off and trypsinization stopped with 10% fetal calf
serum. The tissue was filtrated (40mm) to separate cells from hair.
Cells were suspended in KGM2 complete (1 supplements, 0.06 mM
Ca2þ , 20 ng ml 1 mEGF, 1mg ml 1 cholera toxin, 100 U ml 1
penicillin, and 100mg ml 1 streptomycin; PromoCell, Heidelberg,
Germany) and cultured at 37 1C and 5% CO2 under standard tissue
culture conditions. For experiments, cells after the first passage
were grown to 80–90% confluence and were then further stimulated
as indicated.
Barrier disruption of mouse skin
For barrier disruption experiments, 6- to 8-week-old male SKH-1
mice were used. One flank of each mouse was barrier-disrupted by
repeated tape-stripping or acetone treatment until a 6- to 8-fold
increase in transepidermal water loss (Tewameter TM 210; Courage &
Khazaka, Cologne, Germany) was found. Directly and 6 hours after
barrier disruption, skin samples were harvested.
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